Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis
Hyung J. Chun, … , Euan A. Ashley, Thomas Quertermous
Hyung J. Chun, … , Euan A. Ashley, Thomas Quertermous
Published September 2, 2008
Citation Information: J Clin Invest. 2008;118(10):3343-3354. https://doi.org/10.1172/JCI34871.
View: Text | PDF
Research Article Cardiology

Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis

  • Text
  • PDF
Abstract

Apelin and its cognate G protein–coupled receptor APJ constitute a signaling pathway with a positive inotropic effect on cardiac function and a vasodepressor function in the systemic circulation. The apelin-APJ pathway appears to have opposing physiological roles to the renin-angiotensin system. Here we investigated whether the apelin-APJ pathway can directly antagonize vascular disease-related Ang II actions. In ApoE-KO mice, exogenous Ang II induced atherosclerosis and abdominal aortic aneurysm formation; we found that coinfusion of apelin abrogated these effects. Similarly, apelin treatment rescued Ang II–mediated increases in neointimal formation and vascular remodeling in a vein graft model. NO has previously been implicated in the vasodepressor function of apelin; we found that apelin treatment increased NO bioavailability in ApoE-KO mice. Furthermore, infusion of an NO synthase inhibitor blocked the apelin-mediated decrease in atherosclerosis and aneurysm formation. In rat primary aortic smooth muscle cells, apelin inhibited Ang II–mediated transcriptional regulation of multiple targets as measured by reporter assays. In addition, we demonstrated by coimmunoprecipitation and fluorescence resonance energy transfer analysis that the Ang II and apelin receptors interacted physically. Taken together, these findings indicate that apelin signaling can block Ang II actions in vascular disease by increasing NO production and inhibiting Ang II cellular signaling.

Authors

Hyung J. Chun, Ziad A. Ali, Yoko Kojima, Ramendra K. Kundu, Ahmad Y. Sheikh, Rani Agrawal, Lixin Zheng, Nicholas J. Leeper, Nathan E. Pearl, Andrew J. Patterson, Joshua P. Anderson, Philip S. Tsao, Michael J. Lenardo, Euan A. Ashley, Thomas Quertermous

×

Figure 3

Apelin inhibits Ang II–mediated progression of atherosclerosis in a vein graft model.

Options: View larger image (or click on image) Download as PowerPoint
Apelin inhibits Ang II–mediated progression of atherosclerosis in a vein...
(A) Top row shows representative images of the vein graft cross sections stained with Masson/Goldner. Neointimal area, total vessel wall area, and neointimal vessel area were determined and compared among the experimental groups indicated. Apelin infusion significantly decreased each of these parameters compared with saline control group (*P < 0.05, **P < 0.001). Ang II infusion significantly increased all parameters in comparison to the control group (#P < 0.05), and this effect was significantly inhibited when apelin was administered along with Ang II (†P < 0.05, ††P < 0.001). Neointima/vessel area ratios demonstrate that the beneficial effect of apelin treatment is more pronounced on neointimal hyperplasia. White arrows denote neointima and black arrows denote total vessel wall thickness. Scale bar: 100 μm. (B) SMC contribution to vascular wall disease was assessed by measuring the area occupied by SMC α-actin–stained cells in serial sections. Micrographs show representative images of the vein graft cross sections stained with α-actin antibody. Infusion of Ang II increased SMC content (##P < 0.01). Apelin infusion decreased the measured SMC component of the vessel cross-sectional area (**P < 0.001) compared with saline-treated animals and also decreased the SMC area when combined with Ang II infusion compared with Ang II infusion alone (††P < 0.001). Black arrows denote α-actin–positive staining. Scale bar: 100 μm. (C) The contribution of SMCs was also assessed as a proportion of the total vessel wall area. Apelin infusion decreased the proportion of SMC (*P < 0.05) compared with saline-treated animals and also decreased the SMC proportion when combined with Ang II infusion (††P < 0.001) compared with Ang II infusion alone.

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts